Geneos Wealth Management’s ProShares MSCI Emerging Markets Dividend Growers ETF EMDV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-100
Closed -$5K 2795
2021
Q3
$5K Sell
100
-100
-50% -$5.93K ﹤0.01% 2441
2021
Q2
$12K Hold
200
﹤0.01% 2123
2021
Q1
$11K Hold
200
﹤0.01% 2331
2020
Q4
$12K Hold
200
﹤0.01% 2139
2020
Q3
$9K Hold
200
﹤0.01% 1975
2020
Q2
$9K Hold
200
﹤0.01% 1942
2020
Q1
$8K Hold
200
﹤0.01% 1882
2019
Q4
$12K Hold
200
﹤0.01% 1888
2019
Q3
$11K Hold
200
﹤0.01% 1849
2019
Q2
$11K Sell
200
-200
-50% -$11.5K ﹤0.01% 1869
2019
Q1
$23K Hold
400
﹤0.01% 1499
2018
Q4
$21K Hold
400
﹤0.01% 1485
2018
Q3
$21K Buy
400
+200
+100% +$11.2K ﹤0.01% 1547
2018
Q2
$11K Hold
200
﹤0.01% 1676
2018
Q1
$12K Hold
200
﹤0.01% 1572
2017
Q4
$11K Hold
200
﹤0.01% 1597
2017
Q3
$10K Hold
200
﹤0.01% 1567
2017
Q2
$10K Buy
+200
New +$10.4K ﹤0.01% 1526

Other funds holding EMDV

Geneos Wealth Management's EMDV Position: Q4 2021 in Review

Geneos Wealth Management sold out of ProShares MSCI Emerging Markets Dividend Growers ETF (EMDV) in Q4 2021, closing a stake of 100 shares — an estimated $5K sold.

Geneos Wealth Management first reported a position in EMDV in Q2 2017 and held it in 18 quarters. The position peaked at $23K in Q1 2019. 21 funds tracked by Wall St. Rank hold EMDV as of Q4 2021.

  • Geneos Wealth Management reported no remaining ProShares MSCI Emerging Markets Dividend Growers ETF position as of Q4 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 100 ProShares MSCI Emerging Markets Dividend Growers ETF shares in Q4 2021, an estimated $5K.
  • Geneos Wealth Management first reported a position in ProShares MSCI Emerging Markets Dividend Growers ETF in Q2 2017 and held it in 18 quarters.
  • Geneos Wealth Management's ProShares MSCI Emerging Markets Dividend Growers ETF position peaked at $23K in Q1 2019.
  • 21 funds tracked by Wall St. Rank held ProShares MSCI Emerging Markets Dividend Growers ETF as of Q4 2021.

Based on Geneos Wealth Management's 13F filing for Q4 2021, filed 9 Feb 2022.